论文部分内容阅读
Background: Adverse drug reactions (ADRs) is one of the main causes of new drug discovery failure.Therefore, it is desired to evaluate drug (or candidate) safety in early laboratory stage before they reach further pre-clinical or clinical stages of drug discovery.